We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+34.04%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.89B
AUM Growth
+$163M
Cap. Flow
+$27.4M
Cap. Flow %
0.71%
Top 10 Hldgs %
73.49%
Holding
43
New
3
Increased
8
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$83.2M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$31.1M
3
ERAS icon
Erasca
ERAS
+$23M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$19.1M
5
PVLA
Palvella Therapeutics
PVLA
+$16.7M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$70.9M
2
ABVX
Abivax
ABVX
+$51M
3
RAPT
RAPT Therapeutics
RAPT
+$33.3M
4
RVMD icon
Revolution Medicines
RVMD
+$12.3M
5
TVTX icon
Travere Therapeutics
TVTX
+$9.23M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$5.98B
$709M 18.25%
7,679,684
+884,563
+13% +$83.2M
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.27B
$542M 13.96%
16,943,774
– –
ERAS icon
3
Erasca
ERAS
$6.21B
$399M 10.27%
24,675,188
+1,945,752
+9% +$23M
BBIO icon
4
BridgeBio Pharma
BBIO
$15.7B
$256M 6.59%
3,448,139
-97,418
-3% -$7.06M
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.12B
$233M 5.99%
9,874,511
– –
MBX
6
MBX Biosciences
MBX
$3.3B
$199M 5.11%
6,652,013
– –
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$712M
$139M 3.56%
12,466,489
– –
MAZE
8
Maze Therapeutics
MAZE
$1.69B
$136M 3.51%
4,567,274
– –
KRYS icon
9
Krystal Biotech
KRYS
$10.5B
$124M 3.2%
481,307
-7,153
-1% -$1.9M
TRVI icon
10
Trevi Therapeutics
TRVI
$2.56B
$119M 3.05%
9,939,547
-319,862
-3% -$3.58M
PVLA
11
Palvella Therapeutics
PVLA
$2.14B
$110M 2.83%
882,400
+160,000
+22% +$16.7M
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
$99.9M 2.57%
4,961,108
-78,759
-2% -$1.27M
IRON icon
13
Disc Medicine
IRON
$3.16B
$86.6M 2.23%
1,354,852
+94,852
+8% +$6.58M
CYTK icon
14
Cytokinetics
CYTK
$10.8B
$76.4M 1.97%
1,159,879
+225,237
+24% +$14.3M
RVMD icon
15
Revolution Medicines
RVMD
$45.3B
$65.7M 1.69%
675,686
-121,769
-15% -$12.3M
DYN icon
16
Dyne Therapeutics
DYN
$4.92B
$57.2M 1.47%
3,153,082
– –
SVRA icon
17
Savara
SVRA
$1.15B
$53.1M 1.37%
9,720,852
-141,449
-1% -$787K
TARS icon
18
Tarsus Pharmaceuticals
TARS
$3.14B
$51.1M 1.32%
728,644
– –
VOR icon
19
Vor Biopharma
VOR
$1.42B
$45.4M 1.17%
2,543,939
– –
AGIO icon
20
Agios Pharmaceuticals
AGIO
$2.02B
$42.5M 1.09%
1,256,080
-23,674
-2% -$671K
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.51B
$38.2M 0.98%
+4,009,240
New +$31.1M
ZLAB icon
22
Zai Lab
ZLAB
$2.94B
$35.8M 0.92%
1,902,320
– –
AURA icon
23
Aura Biosciences
AURA
$811M
$34.1M 0.88%
5,100,000
– –
ACAD icon
24
Acadia Pharmaceuticals
ACAD
$5.27B
$32M 0.82%
1,438,198
+141,000
+11% +$3.37M
ASND icon
25
Ascendis Pharma A/S
ASND
$16.6B
$30.5M 0.78%
133,333
– –
1
2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2026 Portfolio in Review

As of Q1 2026, Frazier Life Sciences Management held 43 positions worth $3.89B, up 4.4% from $3.72B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Frazier Life Sciences Management's Q1 2026 filing shows 3 new, 8 increased, 10 reduced and 5 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M. The largest sale was Avidity Biosciences, an estimated $70.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Frazier Life Sciences Management's largest Q1 2026 buy was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M.
  • Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $83.2M increase.
  • Frazier Life Sciences Management's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $12.3M.
  • Frazier Life Sciences Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $70.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 73% of its $3.89B portfolio in Q1 2026.
  • Frazier Life Sciences Management opened 3 new positions and closed 5 in Q1 2026.
  • Frazier Life Sciences Management's portfolio value rose 4.4% quarter-over-quarter to $3.89B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.